Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) Stock Ticker

NASDAQ: TRVI · Healthcare · Biotechnology
$14.52-1.81%
USD · as of 2026-09-28 · market cap $2.0B
Open TRVI in TickrDownload for iPhone

TRVI right now

Options expect by Oct 6±5.5%
Options expect by Oct 29±11.5%
Priced in for Nov 12 earnings±13.9%
IV rank (30-day)5% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full TRVI picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on TRVI
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

TRVI stock facts

Ticker symbolTRVI
ExchangeNASDAQ Global Market
SectorHealthcare
IndustryBiotechnology
Market cap$2.0B
CEOJennifer L. Good
Employees34
HeadquartersNew Haven, CT, US
IPO date2019-05-07
Websitewww.trevitherapeutics.com

What you can see for TRVI on Tickr

Live TRVI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TRVI report.

Rankings

Largest Healthcare companiesLargest companies by market cap

TRVI peers

ARDXNVAXORICPGENTERNTRMLUPBWVE

FAQ

What is the ticker symbol for Trevi Therapeutics, Inc.?

The ticker symbol for Trevi Therapeutics, Inc. is TRVI, listed on the NASDAQ Global Market.

What is TRVI?

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough…

HomeExploreMarketLists
All pages